6/29/2020 6:07:10 PM
BioMarin Promotes Brian Mueller To EVP, CFO
6/18/2020 9:43:35 AM
Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $145 Price Target
6/17/2020 9:22:55 AM
BioMarin Announces Addl. Data From Four-year Update Of An Open-label Phase 1/2 Study Of Valoctocogene Roxaparvovec
6/3/2020 4:06:03 PM
Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $145 Price Target
5/11/2020 7:18:36 AM
BioMarin Intends To Offer $500.0 Mln Of Senior Subordinated Convertible Notes Due 2027
5/1/2020 4:41:38 PM
Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $145 Price Target
5/1/2020 4:40:44 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 2021 Estimate To 0.33 From 0.64
5/1/2020 4:40:32 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) 4Q21 Estimate To 0.13 From 0.21
5/1/2020 4:40:17 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) 3Q21 Estimate To 0.10 From 0.18
5/1/2020 4:39:58 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 2Q21 Estimate To 0.06 From 0.14
5/1/2020 4:39:47 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 1Q21 Estimate To 0.04 From 0.12
5/1/2020 4:39:33 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 4Q20 Estimate To 0.00 From 0.12
5/1/2020 4:39:19 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 3Q20 Estimate To 0.00 From 0.07
5/1/2020 4:39:02 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) 2020 Estimate To 0.11 From 0.22
5/1/2020 4:36:47 PM
Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) 2021 Rev. Estimate To 2073.0 M From 2098.7 M
5/1/2020 4:36:30 PM
Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) 4Q21 Rev. Estimate To 536.4 M From 542.9 M